Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study

F. Bérard, M.C. Ferrier Le Bouedec, L. Bouillet, Z. Reguiai, A. Barbaud, F. Cambazard, B. Milpied, B. Pelvet, I. Kasujee, H. Gharbi, J.P. Lacour
  • British Journal of Dermatology, September 2018, Wiley
  • DOI: 10.1111/bjd.16904

The authors haven't yet claimed this publication.

Read Publication

In partnership with: